GT Biopharma series L preferred holders waive redemption rights permanently

GT Biopharma, Inc.

Holders of Series L 10% Convertible Preferred Stock waived redemption rights under Section 10 of the Certificate of Designations.
Waivers were provided on September 17, 18, and 23, 2025, and are permanent.
Waiver does not affect other rights of the preferred stockholders under the Certificate of Designations.
The company requested the waiver; certain holders countersigned the form of waiver.

item 3.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.